A number of new triclosan-conjugated analogs bearing biodegradable ester linkage have been synthesized, characterized and evaluated for their antimalarial and antibacterial activities. Many of these compounds exhibit good inhibition against Plasmodium falciparum and Escherichia coli. Among them tertiary amine containing triclosan-conjugated prodrug (5) inhibited both P. falciparum (IC50; 0.62 mu M) and E. coli (IC50; 0.26 mu M) at lower concentrations as compared to triclosan. Owing to the presence of a cleavable ester moiety, these new prodrugs are hydrolyzed under physiological conditions and parent molecule, triclosan, is released. Further, introduction of tertiary/quatemary functionality increases their cellular uptake. These properties impart them with higher potency to their antimalarial as well as antibacterial activities. The best compound among them 5 shows close to four-fold enhanced activities against P. falciparum and E. coli cultures as compared to triclosan. (C) 2008 Elsevier Ltd. All rights reserved.
Halogenophenyl glyceride esters
申请人:IMPERIAL CHEMICAL INDUSTRIES PLC
公开号:EP0099177B1
公开(公告)日:1986-08-27
US4587262A
申请人:——
公开号:US4587262A
公开(公告)日:1986-05-06
Triclosan-based supramolecular hydrogels as nanoantibiotics for enhanced antibacterial activity
vitro broad-spectrum antibacterial activities against both Gram-positive and Gram-negative bacteria based on the cooperative effect of antibiotic TCS and the nanostructure-induced bacterial membrane disruption. Furthermore, the TCS-based supramolecular hydrogel nanoantibiotics exhibited enhancedantibacterial activities with low side effects, according to the in vivo antibacterial evaluation at the macro
Halogenophenyl glyceride esters for use in the prophylaxis and/or
申请人:Imperial Chemical Industries PLC
公开号:US04587262A1
公开(公告)日:1986-05-06
The invention concerns novel glyceride esters of anti-bacterial halogenated phenols having the formula I in which Ra and Rb are independently (3-20C)alkyl or (3-20C)alkenyl; Rc and Rd are independently chloro or bromo; Re is hydrogen, chloro or bromo; and A is (1-6C)alkylene optionally bearing one or two (1-4C)alkyl substituents. The esters are of use in the prophylaxis and/or therapy of acne vulgaris. Pharmaceutical compositions for topical administration and processes for the manufacture of the esters are also provided.